Ping-Chiao Tsai, Ph.D.
Affiliations: | 2012 | Roswell Park . Microbiology and Immunology | State University of New York, Buffalo, Buffalo, NY, United States |
Area:
Oncology, Molecular Biology, ImmunologyGoogle:
"Ping-Chiao Tsai"Parents
Sign in to add mentor| Myron S. Czuczman | grad student | 2012 | SUNY Buffalo | |
| (Regulation of CD20 in rituximab-resistant cell lines (RRCL) and B-cell non-Hodgkin's lymphoma (B-NHL).) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Liu Y, Gu JJ, Yang L, et al. (2020) The adhesion molecule ICAM-1 in diffuse large B-cell lymphoma post-rituximab era: relationship with prognostic importance and rituximab resistance. Aging. 12 |
| Huang WT, Weng SW, Huang CC, et al. (2012) Expression of Toll-like receptor9 in diffuse large B-cell lymphoma: further exploring CpG oligodeoxynucleotide in NFκB pathway. Apmis : Acta Pathologica, Microbiologica, Et Immunologica Scandinavica. 120: 872-81 |
| Chou MH, Chuang JH, Eng HL, et al. (2012) Effects of hepatocyte CD14 upregulation during cholestasis on endotoxin sensitivity. Plos One. 7: e34903 |
| Tsai PC, Hernandez-Ilizaliturri FJ, Bangia N, et al. (2012) Regulation of CD20 in rituximab-resistant cell lines and B-cell non-Hodgkin lymphoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 18: 1039-50 |
| Barth MJ, Hernandez-Ilizaliturri FJ, Mavis C, et al. (2012) Ofatumumab demonstrates activity against rituximab-sensitive and -resistant cell lines, lymphoma xenografts and primary tumour cells from patients with B-cell lymphoma. British Journal of Haematology. 156: 490-8 |
| Barth MJ, Pendurti G, Tsai P, et al. (2012) Ofatumumab (OFA) Is a Novel Anti-CD20 Monoclonal Antibody (mAb) with Improved Anti-Tumor Activity in Vitro and in Vivo in Mantle Cell Lymphoma (MCL) Pre-Clinical Models. Blood. 120: 2757-2757 |
| Miller J, Barth MJ, Mavis C, et al. (2012) Ublituximab (TGTX-1101), A Novel Anti-CD20 Monoclonal Antibody (mAb), Demonstrates Activity in Rituximab-Sensitive and Rituximab–resistant B Non-Hodgkin Lymphoma (B-NHL) Pre-Clinical In vitro and in Vivo models. Blood. 120: 2756-2756 |
| Brem EA, Thudium K, Khubchandani S, et al. (2011) Distinct cellular and therapeutic effects of obatoclax in rituximab-sensitive and -resistant lymphomas. British Journal of Haematology. 153: 599-611 |
| Barth MJ, Hernandez-Ilizaliturri FJ, Mavis C, et al. (2010) Activity of ofatumumab (OFA), a fully human monoclonal antibody targeting CD20, against rituximab (RTX)-sensitive (RSCL) and rituximab-resistant cell lines (RRCL), in vivo, and primary tumor cells derived from patients with B-cell lymphoma. Journal of Clinical Oncology. 28: 8095-8095 |
| Riaz W, Hernandez-Ilizaliturri FJ, Mavis C, et al. (2010) Efficacy of combination of rituximab (R), obatoclax (O), and bortezomib (B) against rituximab-sensitive (RSCL) and rituximab-resistant B-cell lymphoma cell lines (RRCL). Journal of Clinical Oncology. 28: 8094-8094 |